DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT07504172

TIRZ-DOSE-NL

Not yet recruiting

Real-world Effectiveness and Dosing Patterns of Tirzepatide in People With Obesity

Real-world Effectiveness and Dosing Patterns of Tirzepatide: A Multicentre Retrospective Observational Study in the Netherlands

Asset

Tirzepatide

Subcutaneous · GLP-1 / GIP dual

Listed sites

10

Recruiting sites

—

Enrollment

1,700

estimated

Study population

Obesity / overweight

Key I/E criterion

•BMI ≥30

Primary endpoint

•Body weight, % change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07504172
Org study ID202508

Timeline

Milestones

Study first posted2026-03-31actual
Last update posted2026-03-31actual
Study start2026-04-01estimated
Primary completion2026-07-01estimated
Study completion2026-08-01estimated

Assets

Investigational agents

Tirzepatide

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersNot accepted
Sampling methodNon probability sample

Study population text

Outpatient clinic

Inclusion criteria

•Adults (age ≥18 years old)
•A BMI of ≥ 30 kg/m2 or a BMI ≥ 27 kg/m2 with at least one obesity complication (e.g., hypertension, dyslipidaemia)

Exclusion criteria

•Pregnant women or pregnancy during treatment
•Previously treated for obesity (with pharmacotherapy, endoscopic treatment or metabolic-bariatric surgery)
•Patients with diabetes

Endpoints (7)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition
4
Other (unclassified)
3

Weight & body composition

4 endpoints
Primary/protocol endpoint

Weight change

Time frame:Baseline-6 months

Body weight, % change

percent change from baseline, improvement

Secondary/protocol endpoint

Changes in body composition

Time frame:Basline-6 months

change from baseline, improvement

Secondary/protocol endpoint/low confidence

Weight loss by maintenance dose

Time frame:Baseline-6 months

change from baseline, improvement

Secondary/protocol endpoint

Weigth

Time frame:Baseline-6 months

Body weight, absolute change (kg)

change from baseline, improvement

Other (unclassified)

3 endpoints
Secondary/protocol endpoint

Demographic and clinical characteristics

Time frame:Baseline

descriptive

Secondary/protocol endpoint/low confidence

Tirzepatide dosing patterns

Time frame:Baseline-6 months

descriptive

Secondary/protocol endpoint/low confidence

Height

Time frame:Baseline-6 months

change from baseline, descriptive

Publications (3)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.